Literature DB >> 20837749

The use of eGFR and ACR to predict decline in renal function in people with diabetes.

Richard A Hoefield1, Philip A Kalra, Patricia G Baker, Ines Sousa, Peter J Diggle, Martin J Gibson, Donal J O'Donoghue, Rachel J Middleton, John P New.   

Abstract

BACKGROUND: There have been few attempts to estimate progression of kidney disease in people with diabetes in a single large population with predictive modelling. The aim of this study was to investigate the rate of progression of chronic kidney disease in people with diabetes according to their estimated glomerular filtration rate (eGFR) and presence of albuminuria.
METHODS: Data were collected on all people with diabetes in Salford, UK, where an eGFR could be calculated using the four-variable MDRD formula and urinary albumin-creatinine ratio (uACR) was available. All data between 2001 and 2007 were used in the model. Classification of albuminuria status was based on the average of their first two uACR measurements. A longitudinal mixed effect dynamic regression model was fitted to the data. Parameters were estimated by maximum likelihood.
RESULTS: For the analysis of the population, average progression of eGFR, uACR and drug prescribing were available in 3431 people. The regression model showed that in people with diabetes and macroalbuminuria, eGFR declined at 5.7% per annum, while the eGFR of those with microalbuminuria or without albuminuria declined at 1.5% and 0.3% per annum, respectively, independently of age (P < 0.0001).
CONCLUSIONS: The longitudinal effect of time on eGFR showed that people with diabetes and macroalbuminuria have an estimated 19 times more rapid decline in renal function compared with those without albuminuria. This study demonstrates that the progression of kidney disease in diabetic people without albuminuria is relatively benign compared with those with albuminuria.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20837749     DOI: 10.1093/ndt/gfq526

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  26 in total

Review 1.  Risks of rapid decline renal function in patients with type 2 diabetes.

Authors:  Yi-Jing Sheen; Wayne Hh Sheu
Journal:  World J Diabetes       Date:  2014-12-15

Review 2.  Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives.

Authors:  Ankur Jindal; Mariana Garcia-Touza; Nidhi Jindal; Adam Whaley-Connell; James R Sowers
Journal:  Endocrinol Metab Clin North Am       Date:  2013-08-01       Impact factor: 4.741

3.  Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).

Authors:  Takashi Wada; Tatsuo Hosoya; Daisuke Honda; Ryusuke Sakamoto; Kazutaka Narita; Tomomitsu Sasaki; Daisuke Okui; Kenjiro Kimura
Journal:  Clin Exp Nephrol       Date:  2018-01-25       Impact factor: 2.801

4.  The association of ECG and echocardiographic abnormalities with sudden cardiac death in a dialysis patient cohort.

Authors:  Darren Green; James P Ritchie; Nik Abidin; David I New; Philip A Kalra
Journal:  J Nephrol       Date:  2013-12-12       Impact factor: 3.902

5.  Risk of Rapid Kidney Function Decline, All-Cause Mortality, and Major Cardiovascular Events in Nonalbuminuric Chronic Kidney Disease in Type 2 Diabetes.

Authors:  Oyunchimeg Buyadaa; Dianna J Magliano; Agus Salim; Digsu N Koye; Jonathan E Shaw
Journal:  Diabetes Care       Date:  2019-12-03       Impact factor: 19.112

6.  Risk of ESRD and death in patients with CKD not referred to a nephrologist: a 7-year prospective study.

Authors:  Roberto Minutolo; Francesco Lapi; Paolo Chiodini; Monica Simonetti; Elisa Bianchini; Serena Pecchioli; Iacopo Cricelli; Claudio Cricelli; Gaetano Piccinocchi; Giuseppe Conte; Luca De Nicola
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-29       Impact factor: 8.237

Review 7.  Use of metformin in the setting of mild-to-moderate renal insufficiency.

Authors:  Kasia J Lipska; Clifford J Bailey; Silvio E Inzucchi
Journal:  Diabetes Care       Date:  2011-06       Impact factor: 19.112

8.  Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.

Authors:  Simke W Waijer; Priya Vart; David Z I Cherney; Glenn M Chertow; Niels Jongs; Anna Maria Langkilde; Johannes F E Mann; Ofri Mosenzon; John J V McMurray; Peter Rossing; Ricardo Correa-Rotter; Bergur V Stefansson; Robert D Toto; David C Wheeler; Hiddo J L Heerspink
Journal:  Diabetologia       Date:  2022-04-21       Impact factor: 10.460

9.  Extreme Elevations in Blood Pressure and All-Cause Mortality in a Referred CKD Population: Results from the CRISIS Study.

Authors:  James Ritchie; Francesco Rainone; Darren Green; Helen Alderson; Diana Chiu; Rachel Middleton; Donal O'Donoghue; Philip A Kalra
Journal:  Int J Hypertens       Date:  2013-04-22       Impact factor: 2.420

10.  Factors Associated with the Decline of Kidney Function Differ among eGFR Strata in Subjects with Type 2 Diabetes Mellitus.

Authors:  Shu Meguro; Masuomi Tomita; Yusuke Kabeya; Takeshi Katsuki; Yoichi Oikawa; Akira Shimada; Toshihide Kawai; Hiroshi Itoh; Yoshihito Atsumi
Journal:  Int J Endocrinol       Date:  2012-12-18       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.